Skip to main content

Enzymatics Buys ArcherDx for up to $50M

NEW YORK (GenomeWeb News) – Enzymatics today announced it has bought ArcherDx, a developer of kits and software solutions for next-generation sequencing, for up to $50 million.

The deal, consisting of cash, equity, and potential milestones, provides Beverly, Mass.-based Enzymatics with genomics capabilities that complement its Enzymatics Supply Chain Solutions and Enzymatics Reagents groups, it said. The acquisition, the company added, also expands the new Enzymatics Diagnostics groups with technology, kits, and analytical solutions for hospitals, research institutions, and other diagnostic providers for the rapid and cost-effective assessment of genetic biomarkers.

In conjunction with the transaction, ArcherDx Co-founder and CEO Jason Myers is joining Enzymatics as chief scientific officer. ArcherDx is based in Boulder, Colo.

"An unprecedented growth in genomics for healthcare is fueling greater demand for faster, more accurate, and more cost effective sequencing applications," Enzymatics' President and CEO Jon DiVincenzo said in a statement. "We are seeing double-digit growth in the placement of new sequencers every year and broad adoption of genomic technologies across clinical communities. Enzymatics, which already supplies reagents and kits to approximately 80 percent of the NGS industry, together with ArcherDx, will bring novel sequencing applications more directly to clinical researchers."

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.